Form 4: Humacyte Director Acquires 75,000 Stock Options
SEC Form 4 Filing
John Philip Bamforth, a director of Humacyte, Inc., acquired 75,000 stock options on June 13, 2024, exercisable over a four-year period.
Summary
- On June 13, 2024, John Philip Bamforth, a director of Humacyte, Inc., acquired 75,000 stock options.
- The exercise price of these options is $7.20.
- The options become exercisable in tranches, starting with 25% on June 13, 2025.
- The remaining options vest monthly until June 13, 2028.
- The options expire on June 13, 2034.
- Following the transaction, Bamforth directly owns 75,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, indicating standard executive compensation practices.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the stock option acquisition. |
| 06/13/2025 | First 25% of the options become exercisable. |
| 06/13/2028 | End of the monthly vesting period for the options. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.